Anixa Biosciences Inc (ANIX) — SEC Filings
Anixa Biosciences Inc (ANIX) — 16 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 6 10-Q, 5 8-K, 2 DEF 14A.
View Anixa Biosciences Inc on SEC EDGAR
Overview
Anixa Biosciences Inc (ANIX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: Anixa Biosciences, Inc. filed an 8-K on December 12, 2025, reporting an event on December 11, 2025. The filing is a Regulation FD Disclosure and includes Financial Statements and Exhibits. The company, formerly known as ITUS Corp and COPYTELE INC, is incorporated in Delaware and headquartered in San
Sentiment Summary
Across 16 filings, the sentiment breakdown is: 14 neutral, 2 mixed. The dominant filing sentiment for Anixa Biosciences Inc is neutral.
Filing Type Overview
Anixa Biosciences Inc (ANIX) has filed 5 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13D with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (16)
Risk Profile
Risk Assessment: Of ANIX's 15 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $-2.258M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $1.495M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Michael Catelani
- Dr. Amit Kumar
- Dr. Arnold Baskies
- Emily Gottschalk
- Lewis H. Titterton, Jr.
Industry Context
Anixa Biosciences operates in the highly competitive and innovative biotechnology sector, focusing on oncology. The company is developing novel immunotherapies, including CAR-T and cancer vaccines, which are at the forefront of cancer treatment research. This field is characterized by significant R&D investment, long development cycles, and high regulatory hurdles, with major pharmaceutical companies and numerous smaller biotechs vying for breakthroughs.
Top Tags
financials (5) · Biotechnology (3) · corporate-governance (3) · biotech (3) · 10-Q (3) · disclosure (2) · Oncology (2) · R&D Expenses (2) · expenses (2) · 10-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Event Date | 20251211 | Earliest event reported in the 8-K |
| Filing Date | 20251212 | Date the 8-K was filed with the SEC |
| Revenue | $0 | No revenue for three and nine months ended July 31, 2025 and 2024, indicating pre-commercial stage. |
| Net Loss (3 months) | $(2.258)M | Decreased from $(3.277)M in prior year, a 31.1% improvement. |
| Net Loss (9 months) | $(8.232)M | Decreased from $(9.671)M in prior year, a 14.9% improvement. |
| R&D Expenses (9 months) | $3.929M | Decreased from $4.920M in prior year, a 20.2% reduction. |
| G&A Expenses (9 months) | $4.896M | Decreased from $5.748M in prior year, a 14.8% reduction. |
| Cash and Cash Equivalents | $1.495M | Increased from $1.271M at October 31, 2024, providing short-term liquidity. |
| Proceeds from ATM Offering | $1.924M | Contributed to cash increase, demonstrating access to capital. |
| Common Shares Outstanding | 32,916,915 | As of September 10, 2025, reflecting recent equity offerings. |
| Accumulated Deficit | $(248.982)M | As of July 31, 2025, highlighting historical losses and pre-revenue status. |
| Wistar's Equity Stake in Certainty | 4.1% | Diluted from 5% due to Anixa's funding of Certainty's activities. |
| Net Loss (Q2 2025) | $3.74M | Decreased from $4.01M in Q2 2024, representing a 6.7% improvement. |
| Net Loss (YTD 2025) | $7.50M | Decreased from $7.99M in YTD 2024, representing a 6.1% improvement. |
| R&D Expense (Q2 2025) | $2.23M | Decreased by $270,000 or 10.8% from $2.50M in Q2 2024. |
Frequently Asked Questions
What are the latest SEC filings for Anixa Biosciences Inc (ANIX)?
Anixa Biosciences Inc has 16 recent SEC filings from Jan 2024 to Dec 2025, including 6 10-Q, 5 8-K, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ANIX filings?
Across 16 filings, the sentiment breakdown is: 14 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Anixa Biosciences Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Anixa Biosciences Inc (ANIX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Anixa Biosciences Inc?
Key financial highlights from Anixa Biosciences Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ANIX?
The investment thesis for ANIX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Anixa Biosciences Inc?
Key executives identified across Anixa Biosciences Inc's filings include Michael Catelani, Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, Lewis H. Titterton, Jr..
What are the main risk factors for Anixa Biosciences Inc stock?
Of ANIX's 15 assessed filings, 2 were flagged high-risk, 8 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Anixa Biosciences Inc?
Forward guidance and predictions for Anixa Biosciences Inc are extracted from SEC filings as they are enriched.